Point72 Asset Management
MYGN icon

Point72 Asset Management’s Myriad Genetics MYGN Stock Holding History

Point72 Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-400,000
Closed -$2.12M – 2555
2025
Q2 		$2.12M Buy
+400,000
New +$2.36M ﹤0.01% 1286

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management's MYGN Position: Q1 2026 in Review

Point72 Asset Management reduced its Myriad Genetics (MYGN) stake by 22% in Q1 2026, selling an estimated $1.43M and leaving 957,901 shares worth $4.31M. The position accounts for 0.01% of the portfolio, ranked #1796.

Point72 Asset Management first reported a position in MYGN in Q4 2014 and has held it in 32 quarters since. The position peaked at $31.2M in Q2 2018. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Point72 Asset Management held 957,901 shares of Myriad Genetics worth $4.31M as of Q1 2026.
  • Point72 Asset Management sold 274,767 Myriad Genetics shares in Q1 2026, an estimated $1.43M.
  • Myriad Genetics made up 0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1796 holding.
  • Point72 Asset Management first reported a position in Myriad Genetics in Q4 2014 and has held it in 32 quarters since.
  • Point72 Asset Management's Myriad Genetics position peaked at $31.2M in Q2 2018.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.